anti-doping testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Similarly, focal adhesions occur between the undersurface of the greater omentum and the cephalad aspect of the transverse mesocolon. These can be accessed after dividing the peritoneal fold that links the greater omentum and transverse colon. Adhesions here must be divided to separate the greater omentum off the transverse mesocolon, thus allowing access to the lesser sac proper. The fetal sigmoid colon mesentery can be visualised during routine ultrasound examination from the 12th week of pregnancy.
== Invertebrates == In insects, synephrine has been found to be a very potent agonist at many invertebrate octopamine receptor preparations, and is even more potent than octopamine at a locust (Schistocerca americana gregaria) nerve-muscle preparation. Synephrine (racemic) is also more potent than octopamine (racemic) at inducing light-emission in the firefly (Photinus species) light organ. Synephrine exhibits similarly high potency in stimulating adenylate cyclase activity and in decreasing clotting time in lobster (Homarus americanus) hematocytes. Racemic synephrine was found to increase cAMP in the abdominal epidermis of the blood-sucking bug, Rhodnius prolixus. Rachinsky reported that synephrine was equipotent with octopamine in stimulating JH (juvenile hormone) release in the corpora allata of honey bee (Apis mellifera), but Woodring and Hoffmann found that synephrine had no effect on the synthesis of JH III, in in vitro preparations from the cricket, Gryllus bimaculatus.
Historian Eduardo Torres Cuevas has written:"A question arises during this period: Was it possible that individuals within the island's power structure were linked to Freemasonry? Much remains to be studied in this regard. The fact that, during those years, the Cuban political government, as well as a significant portion of the emerging Havana oligarchy, were closely linked to the Count of Aranda's group in Spain, gave rise to the hypothesis that some of its members were Freemasons and, therefore, held meetings in Cuba... This hypothesis appears to have faded after the work of Dr. José Antonio Ferrer Benimeli, who clarifies the historical enigma of the Count of Aranda as a Freemason."In 1767, in mainland Spain, the Grand Logia Española changed its name to Gran Oriente and was recognized by the Grand Lodge of England.
Sources: en.wikipedia.org
According to studies published in 2021 by Charles Marshall et al., the total population of adult Tyrannosaurus at any given time was perhaps 20,000 individuals, with computer estimations also suggesting a total population no lower than 1,300 and no higher than 328,000. The authors themselves suggest that the estimate of 20,000 individuals is probably lower than what should be expected, especially when factoring in that disease pandemics could easily wipe out such a small population. Over the span of the genus' existence, it is estimated that there were about 127,000 generations, totalling roughly 2.5 billion animals. In the same paper, it is suggested that in a population of Tyrannosaurus adults numbering 20,000, the number of individuals living in an area the size of California could be as high as 3,800 animals, while an area the size of Washington D.C. could support a population of only two adult Tyrannosaurus. The study does not take into account the number of juvenile animals present due to their occupation of a different niche than the adults, and thus it is likely the total population was much higher. Simultaneously, studies of living carnivores suggest that some predator populations are higher in density than others of similar weight (such as jaguars and hyenas, which have vastly differing population densities). Lastly, the study suggests that in most cases, only one in 80 million Tyrannosaurus would become fossilized, while the chances were likely as high as one in every 16,000 of an individual becoming fossilized in areas that had more dense populations.
== Reactivity == As a simple, abundant and bifunctional compound, pyruvic acid has been shown to participate in many reactions. Pyruvate reacts with amino acids to give alanine by the process called transamination:
==== Hoji ==== Houji Tomasu (戸増 宝児, Tomasu Hōji), also known simply as "Hoji" (ホージー, Hōjī), is the professional, yet arrogant and stubborn, second-in-command and sniper of the team who serves as Deka Blue (デカブルー, Deka Burū). While he is reserved about his personal life and shows little emotion to prevent both from interfering with his work, he has a tendency to blurt out English phrases such as "Perfect!", "Unbelievable!", and "Super cool!". Due to their differing personalities, Hoji clashes with Ban early in the series, though Hoji slowly warms up to, and becomes friends with, Ban. Later in the series, Hoji applies for a gold badge promotion from the Tokkyou division, but ultimately refuses it due to a personal tragedy. In the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Hoji goes undercover as a shut-in after Doggie Kruger's seeming turn to crime to help Ban and Sen-chan restore their leader's reputation. As Deka Blue, Hoji wields the D-Knuckle (ディーナックル, Dī Nakkuru) and the D-Rod (ディーロッド, Dī Roddo) baton, which can combine to form the D-Sniper (ディースナイパー, Dī Sunaipā) rifle. He also rides the Machine Husky (マシンハスキー, Mashin Hasukī) police motorcycle. Using the D-Rod, Hoji can perform the Blue Finish (ブルーフィニッシュ, Burū Finisshu) attack. Hoji is portrayed by Tsuyoshi Hayashi (林 剛史, Hayashi Tsuyoshi).
== Corporate structure == TikTok Ltd was incorporated in the Cayman Islands in the Caribbean and is based in both Singapore and Los Angeles. It owns entities which are based respectively in Australia (which also runs the New Zealand business), United Kingdom (also owns subsidiaries in the European Union), and Singapore (owns operations in Southeast Asia and India). A spin-off company, TikTok USDS Joint Venture LLC was formed on 22 January 2026 to handle TikTok and other ByteDance properties in the United States. Oracle Corporation, MGX Fund Management Limited, Silver Lake each hold a 15% stake, ByteDance holds a 19.9% stake, and the remaining 35.1% is shared between Dell Technologies founder Michael Dell and Vastmere Strategic Investments. Its parent company, Beijing-based ByteDance, is owned by founders and Chinese investors, other global investors, and employees. One of ByteDance's main domestic subsidiaries is owned by Chinese state funds and entities through a 1% golden share. Employees have reported that multiple overlaps exist between TikTok and ByteDance in terms of personnel management and product development. TikTok says that since 2020, its US-based CEO is responsible for making important decisions, and has downplayed its China connection.
Sources: en.wikipedia.org
==== Reactions and political crisis ==== However, rather than address concerns, Héctor Valer's nomination amplified the political crisis. On 3 February 2022, it was revealed that Valer had been the subject of two complaints of violence by his wife and daughter in 2016, over which a court had granted him protection in 2017. In a press conference, Valer denied the allegations alleging lack of evidence or convictions, and defended himself by saying he had only "reprimanded" his daughter without violence. Later the same night, all parliamentary groups (i.e., FP, AP, AvP, RP and PP, except SP whose group is divided between support and distrust) officially condemned the acts committed and announced that they would not grant a vote of confidence to the Valer. The following day, 4 February 2022, the ruling party Free Peru decided after not to grant a vote of confidence to Valer. A few hours later, the four members of the Together for Peru group, with the exception of the minister and deputy Roberto Sánchez, also decided not to grant the vote of confidence. Despite the extent of the political crisis, Héctor Valer announced at 11:00am on 4 February 2022 that he would attend Congress the following day to request a vote of confidence. In reaction, the President of Congress Maricarmen Alva rejected the possibility of a vote of confidence the following day.
=== Music === Mass (band), an English post-punk band Mass (music), a choral composition that sets liturgical text to music Mass (Stravinsky), a composition by Igor Stravinsky Mass (Bernstein), a musical theater work by Leonard Bernstein Mass (Grotus album), 1996 Mass (The Gazette album), 2021 The Mass (album), by musical project Era Mass, a 2011 album by New Zealand musician Alastair Galbraith
Åland Islands Peace Institute Demos Helsinki European Centre of Excellence for Countering Hybrid Threats (Hybrid CoE) Crisis Management Initiative (CMI) Research Institute of the Finnish Economy (Etla) Finnish Institute of International Affairs In addition to specific independent think tanks, the largest political parties have their own think tank organizations. This is mainly due to support granted by state for such activity. The corporate world has focused their efforts to central representative organization Confederation of Finnish Industries, which acts as think tank in addition to negotiating salaries with workers unions. Furthermore, there is the Finnish Business and Policy Forum (Elinkeinoelämän valtuuskunta, EVA). Agricultural and regional interests, associated with The Central Union of Agricultural Producers and Forest Owners (Maa- ja metsätaloustuottajain Keskusliitto, MTK) and the Centre Party, are researched by Pellervo Economic Research (Pellervon taloustutkimus, PTT). The Central Organisation of Finnish Trade Unions (Suomen Ammattiliittojen Keskusjärjestö, SAK) and the Social Democratic Party are associated with the Labour Institute for Economic Research (Palkansaajien tutkimuslaitos, PT). Each of these organizations often release forecasts concerning the national economy.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.